B · Normal
[Yiling Pharmaceutical: The innovative chemical drug LB220-D08 sustained-release tablets were approved for clinical trials] On October 20, Yiling Pharmaceutical (002603.SZ) announced that the company received the "Drug Clinical Trial Approval Notice" approved and issued by the State Food and Drug Administration, and the innovative chemical drug LB220-D08 sustained-release tablets were approved to conduct clinical trials for atypical hemolytic uremic syndrome (aHUS). This drug is a Class 1 new chemical drug independently developed by the company. It is a complement inhibitor targeting Factor B factor and has independent intellectual property rights.
A-share announcement express 🕐 2026-10-20 16:02
#clinical trial #Chemical #A-share announcement express
Save as Image Generate a beautiful long image to share on Moments or in group chats Generate now ⬇
← Back to Telegraph

Related telegraphs

[Zhongfu Industrial: Net profit in the first three quarters increased by 147.95% 10-20 17:29 [4-Connect Jidazhengyuan: In the fields of artificial intelligence security, ant 10-20 17:28 [Hongchang Electronics: Plans to invest 800 million yuan in high-end copper clad 10-20 17:24 [CSSC Defense: 35.799 billion yuan in new orders received in the first three qua 10-20 17:24 [Times Wanheng: Net loss in the first three quarters was 11.332 million yuan] On 10-20 17:16 [Sany Heavy Energy: Net profit in the first three quarters increased by 204.15% 10-20 17:12

Comments

0/500
Captcha (click to refresh)
No comments yet